脂蛋白(a)水平与首次缺血性卒中后复发性血管事件
本研究基于柏林C&S前瞻性队列中250例首次急性缺血性卒中患者,检测血清Lp(a)水平并以>30 mg/dL为升高标准,随访12个月。结果显示Lp(a)升高者复发性联合血管事件风险显著更高(调整后HR 2.60,95%CI 1.19-5.67,P=0.016),需在更大多中心试验中验证。
要点
- 首次缺血性卒中后Lp(a)>30 mg/dL与复合血管事件复发风险升高相关(调整后HR 2.60)。
- Lp(a)升高组复发事件中位时间48天,正常组161天,提示早期风险。
- 该发现支持在卒中幸存者中检测Lp(a)以评估残余血管风险。
核心结论
- 在首次急性缺血性卒中患者中,Lp(a)水平升高与复合血管事件复发风险增加独立相关。
研究设计与样本
- 前瞻性柏林C&S研究(2009年1月至2014年8月)的亚组分析,纳入250例有12个月随访数据和储存血样的急性缺血性卒中患者。
- 采用不敏感于异构体的散射比浊法测定血清Lp(a)水平。
主要发现
- 250例患者中26例(10%)在随访期间发生复发性血管事件。
- Lp(a)正常组157例中11例(7%)发生事件,中位时间161天(IQR 19-196天)。
- Lp(a)升高组93例中15例(16%)发生事件,中位时间48天(IQR 9-194天),P=0.026。
- 调整潜在混杂因素后,Lp(a)升高组复发事件风险显著更高(HR 2.60,95%CI 1.19-5.67,P=0.016)。
关键数值与推荐
- Lp(a)升高定义为>30 mg/dL。
- 复合血管终点包括缺血性卒中、短暂性脑缺血发作、心肌梗死、非择期冠状动脉血运重建和心血管死亡。
临床怎么用
- 对首次缺血性卒中患者可考虑检测Lp(a)水平以识别残余血管风险较高的个体。
- Lp(a)升高者可能需要更密切的随访和强化二级预防,但尚需验证性研究支持。
局限性
- 本研究为单中心前瞻性队列的亚组分析,样本量有限(250例)。
- 作者指出该发现需在更大多中心试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The association of elevated lipoprotein(a) (Lp(a)) levels and the incidence of cardiovascular disease, especially coronary heart disease and ischemic stroke, is well established. However, evidence on the association between Lp(a) levels and residual vascular risk in stroke survivors is lacking. We aimed to elucidate the risk for recurrent cardiovascular and cerebrovascular events in the patients with first-ever ischemic stroke with elevated Lp(a). METHODS: All patients with acute ischemic stroke who participated in the prospective Berlin C&S study (Cream & Sugar) between January 2009 and August 2014 with available 12-month follow-up data and stored blood samples were eligible for inclusion. Lp(a) levels were determined in serum samples using an isoform-insensitive nephelometry assay. We assessed the risk for the composite vascular end point of ischemic stroke, transient ischemic attack, myocardial infarction, nonelective coronary revascularization, and cardiovascular death with elevated Lp(a) defined as >30 mg/dL using Cox regression analyses. RESULTS: Of 465 C&S study participants, 250 patients were included into this substudy with a median National Institutes of Health Stroke Scale score of 2 (1-4). Twenty-six patients (10%) experienced a recurrent vascular event during follow-up. Among patients with normal Lp(a) levels, 11 of 157 subjects (7%) experienced an event at a median time of 161 days (interquartile range, 19-196 days), whereas in patients with elevated Lp(a) levels, 15 of 93 subjects (16%) experienced an event at a median time of 48 days (interquartile range, 9-194 days; P=0.026). The risk for a recurrent event was significantly higher in patients with elevated Lp(a) levels after adjustment for potential confounders (hazard ratio, 2.60; 95% confidence interval, 1.19-5.67; P=0.016). CONCLUSIONS: Elevated Lp(a) levels are associated with a higher risk for combined vascular event recurrence in patients with acute, first-ever ischemic stroke. This finding should be validated in larger, multicenter trials. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01378468.
引用
- Lange KS, Nave AH, Liman TG, et al. Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. Stroke. 2016. PMID: 27856951. doi:10.1161/STROKEAHA.116.014436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。